For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $17.93 in the prior trading day, Adma Biologics Inc (NASDAQ: ADMA) closed at $17.7, down -1.28%. In other words, the price has decreased by -$1.28 from its previous closing price. On the day, 2.89 million shares were traded. ADMA stock price reached its highest trading level at $18.33 during the session, while it also had its lowest trading level at $17.47.
Ratios:
Our goal is to gain a better understanding of ADMA by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 68.63 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 103.43. For the most recent quarter (mrq), Quick Ratio is recorded 3.65 and its Current Ratio is at 7.13. In the meantime, Its Debt-to-Equity ratio is 0.19 whereas as Long-Term Debt/Eq ratio is at 0.18.
On October 13, 2022, Mizuho started tracking the stock assigning a Buy rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on November 11, 2021, while the target price for the stock was maintained at $5.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 15 ’25 when Grossman Adam S sold 21,000 shares for $19.79 per share. The transaction valued at 415,590 led to the insider holds 2,007,850 shares of the business.
Grossman Adam S sold 21,000 shares of ADMA for $336,000 on Nov 19 ’25. The President and CEO now owns 2,013,850 shares after completing the transaction at $16.00 per share. On Oct 24 ’25, another insider, Grossman Adam S, who serves as the President and CEO of the company, sold 21,000 shares for $16.00 each. As a result, the insider received 336,000 and left with 2,019,850 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADMA now has a Market Capitalization of 4223763968 and an Enterprise Value of 4234298368. As of this moment, Adma’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.79, and their Forward P/E ratio for the next fiscal year is 19.78. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.56. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.62 while its Price-to-Book (P/B) ratio in mrq is 9.78. Its current Enterprise Value per Revenue stands at 8.667 whereas that against EBITDA is 24.195.
Stock Price History:
The Beta on a monthly basis for ADMA is 0.48, which has changed by 0.073010206 over the last 52 weeks, in comparison to a change of 0.1726681 over the same period for the S&P500. Over the past 52 weeks, ADMA has reached a high of $25.67, while it has fallen to a 52-week low of $13.50. The 50-Day Moving Average of the stock is -1.30%, while the 200-Day Moving Average is calculated to be -2.34%.
Shares Statistics:
The stock has traded on average 3.08M shares per day over the past 3-months and 2380500 shares per day over the last 10 days, according to various share statistics. A total of 238.33M shares are outstanding, with a floating share count of 229.92M. Insiders hold about 3.40% of the company’s shares, while institutions hold 92.84% stake in the company. Shares short for ADMA as of 1767139200 were 18972317 with a Short Ratio of 6.15, compared to 1764288000 on 18563031. Therefore, it implies a Short% of Shares Outstanding of 18972317 and a Short% of Float of 9.790000000000001.
Earnings Estimates
The company has 1.0 analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $0.2, with high estimates of $0.2 and low estimates of $0.2.
Analysts are recommending an EPS of between $0.6 and $0.6 for the fiscal current year, implying an average EPS of $0.6. EPS for the following year is $0.94, with 1.0 analysts recommending between $0.94 and $0.94.
Revenue Estimates
1 analysts predict $139.8M in revenue. The current quarter. It ranges from a high estimate of $139.8M to a low estimate of $139.8M. As of. The current estimate, Adma Biologics Inc’s year-ago sales were $117.55MFor the next quarter, 1 analysts are estimating revenue of $142.3M. There is a high estimate of $142.3M for the next quarter, whereas the lowest estimate is $142.3M.
A total of 1 analysts have provided revenue estimates for ADMA’s current fiscal year. The highest revenue estimate was $510.8M, while the lowest revenue estimate was $510.8M, resulting in an average revenue estimate of $510.8M. In the same quarter a year ago, actual revenue was $426.45MBased on 1 analysts’ estimates, the company’s revenue will be $635M in the next fiscal year. The high estimate is $635M and the low estimate is $635M.
